Congratulations to the finalists who have been recognized by their peers for the inspiring work they do each day – all to create a brighter future for those living with and affected by cancer.
Stay tuned as the winners are announced during the C2 Awards Ceremony on May 2nd 2019.
C2 Catalyst for Change Award
Finalists for this award bring high-quality cancer care to underserved populations. Consequently, their work drives change at the community-, neighborhood or hospital-level that results in better cancer care for more people.
Dian “CJ” Corneliussen
Founder and Director Emeritus
Dian “CJ” Corneliussen, Founder and Director emeritus, METAvivor
A metastatic breast-cancer (MBC) survivor who served 24 years in the U.S. Air Force, she founded METAvivor to fill a gap of funding and support for this "hopeless" patient population. Today, the organization has awarded 72 grants worth a total of $7,400,000, trained over 100 peer leaders to provide grassroots MBC education and averages 75 peer-to-peer support groups a year.
CJ has also given presentations in Asia, Europe, Mexico and the United States, covering a range of topics, including oncologist-patient communication.
Dora E. Arias
Founder and Executive Director
Curémonos represented by Dora E. Arias, Founder and Executive Director
This organization helps Latinas at each stage of cancer trajectory, including prevention, such as providing breast-health education and access to early detection through free cancer screenings. Curémonos has helped more than 4,000 underserved women, including connecting 2,733 women with education about the importance of breast health, breast-cancer risks, early detection and avenues to treatment. It has also connected 453 uninsured women to free breast-cancer screenings.
Chief Medical Officer
New Orleans East Louisiana Community Health Center
Keith Winfrey, Chief Medical Officer, New Orleans East Louisiana Community Health Center (NOELA); Clinical Assistant Professor of Medicine, Tulane University School of Medicine
One of Keith’s specialties is preventative medicine, and he is a leader in local and state-wide colorectal cancer–screening initiatives in Louisiana. His also volunteers his time to collaborate with local, state and regional partners to improve outcomes for patients.
C2 Catalyst for Care Award
This group of finalists improves the cancer-care experience for patients and their loved ones. As a result, the work of these finalists makes a patient’s experience as easy as possible during an extraordinarily difficult time.
The Centers for Excellence Program of the GO2 Foundation for Lung Cancer
Centers of Excellence Program of the Addario Lung Cancer Foundation represented by Leah Fine, Senior Director
This community hospital program focuses on providing lung-cancer patients with patient-focused coordinated, multidisciplinary care with the expertise of a nurse navigator. COEs currently serve more than 6,000 patients. Since its start in 2014, the COE program has expanded to more than 25 centers in 14 states.
John and Christine Lederer
Zaching Against Cancer Foundation
John and Christine Lederer, Founders, Zaching Against Cancer Foundation (ZACF)
The Lederers founded ZACF with their late son, Zach, who was just 20 years old when he passed away from brain cancer in 2014. The foundation provides support and encouragement to cancer patients of all ages battling all cancers. In 2018, for example, over 2,700 patients participated in the foundation’s complementary therapies, which include massage, music, wellness seminars, days of beauty and meditation.
Patricia Goldsmith, CEO, CancerCare
With more than 20 years of nonprofit management and strategic-planning experience, she has guided the expansion of CancerCare’s free, professional emotional and practical assistance for those affected by cancer. Under her leadership, CancerCare has also amplified patient voices through its Patient Values Initiative, which aims to facilitate patient involvement in the decision-making process and better access to care. In 2018, CancerCare helped 186,700 people affected by cancer in all 50 states.
C2 Catalyst for Precision Medicine Award
A finalist for this award significantly advances precision medicine in oncology to bring new, more personalized tests or treatments to patients. As such, these finalists enhance the ability to provide the right treatment for the right patient at the right time.
Keck School of Medicine of USC
Dana-Farber Cancer Institute
Barbara Gitlitz, Voluntary Faculty, University of Southern California’s Keck School of Medicine
Geoffrey Oxnard, Thoracic Oncologist, Dana-Farber Cancer Institute
Gitlitz and Oxnard conducted the first study of lung cancer in adolescents/young adults (under 40 years old). The Genomics of Young Lung Study (GoYLC) found that about 80% of the young lung-cancer patients had a driver mutation treatable with available targeted therapies or precision medicine.
Janet Freeman-Daily, Lisa Goldman & Tori Tomalia
ROS1ders represented by Janet Freeman-Daily, Lisa Goldman and Tori Tomalia, cofounders
In 2015, three lung-cancer survivors started an online community — a Facebook group called the ROS1ders, which is for people whose tumors have this genetic mutation. Now — through the Facebook page, a website, blogging, social media and networking at conferences — the group has identified more than 400 patients from 20 countries with the ROS1 mutation. Consequently, this patient group makes new research possible.
Executive Vice President & Chief Technology Officer
Roman Yelensky, Executive Vice President and Chief Technology Officer, Gritstone.
Roman oversees Gritstone’s genomics, proteomics and informatics programs. Formerly (as vice president of biomarker and companion diagnostic development, Foundation Medicine), he co-led sequence data analysis for FoundationOne and led validation studies supporting clinical laboratory accreditation and testing more than 100,000 patients. Plus, he established Foundation Medicine’s FDA-regulated products program, leading to the FDA approval of FoundationFocusCDxBRCA, the first companion diagnostic based on next-generation sequencing.